Recent developments of interest in cardiovascular medicine
The GLP-1 receptor agonist dulaglutide (Trulicity) significantly reduced the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in top-line results released from the REWIND trial. Sponsor Eli Lilly touted it as the first cardiovascular outcomes trial to show superiority in a largely primary prevention population with type 2 diabetes.
A critical look at the sausage-making behind the new cardiovascular risk-reduction labelfor canagliflozin (Invokana), from CardioBrief.
Polyvascular disease and type 2 diabetes appeared additive for long-term cardiovascular risk, but ezetimibe (Zetia) worked just as well in these patients, a secondary analysis of the IMPROVE-IT trial
showed. (Lancet Diabetes & Endocrinology
Kentucky cardiologist Anis Chalhoub, MD, was sentenced to 42 months in federal prison followed by 3 years not practicing medicine after being found guilty of fraud related to unnecessary pacemaker implantation. (Department of Justice)
The Apple Heart Study at 1 year has turned out some data on heart rhythm disorder detection, but the biggest questions are not being studied. (Cardiovascular Business, Wired)
Cardiology needs to pay more attention to psychosocial factors -- from unhappy relationships and work stress to poverty and income inequality, says Sandeep Jauhar, MD, PhD, in a review of his book by the New York Times. MedPage Today has more here.
Robotic arm rehabilitation was associated with better speech and language outcomes in chronic stroke patients with aphasia in a small trial substudy in Frontiers in Neurology.
Vitamin D and cardiorespiratory fitness
are linked, but it's not clear if supplementation would help, a National Health and Nutrition Survey-based study suggested. (European Journal of Preventive Cardiology
Plasma levels of cardiac bridging integrator 1 (cBIN1), a marker of transverse tubule dysfunction, could be a novel biomarker for diagnosis of heart failure with preserved ejection fraction. (JAMA Cardiology)
Diagnostic yield of atrial fibrillation screening in elite athletes in Spain was low (21 of 6,813) in a single referral center study in JAMA Cardiology.
Read the original article on Medpage Today: Aphasia Recovery; HFpEF Biomarker